Welcome to the e-CCO Library!

P675: Associations between Inflammatory Bowel Disease, social isolation, and mortality: evidence from UK Biobank cohort study
Year: 2022
Source: ECCO'22
Authors: Chen, J.(1);Geng, J.(1);Wang, J.(2);Fu, T.(2);Sun, Y.(1);Chen, H.(3);Chen, X.(2);Wang, X.(2);Hesketh, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P675: Flavonoid-degrading bacteria have central positions in correlation network analysis in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Pisani, A.(1);Rausch, P.(2);Ellul, S.(3);Bang, C.(2);Tabone, T.(1);Marantidis Cordina, C.(4);Zahra, G.(5);Ellul, P.(1);Franke, A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P675: Follow-up ileocolonoscopy is underused in Crohn’s disease patients after ileocecal resection despite higher total and inpatient health care costs compared with controls without resection
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Schoepfer1, S. Vavricka2*, B. Brüngger3, E. Blozik3, J. Celeiro4, T. Greuter2, C. Bähler3

Created: Thursday, 21 February 2019, 9:14 AM
P675: Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohn's disease and ulcerative colitis – 54 week data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Molnár T.*1, Farkas K.1, Rutka M.1, Ferenci T.2, Nagy F.1, Bálint A.1, Bor R.1, Milassin A.1, Fábián A.1, Végh Z.3, Kürti Z.3, Lakatos P.L.3, Szepes Z.1

Created: Wednesday, 20 February 2019, 10:36 AM
P675: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chaparro Sanchez, M.(1)*;Acosta, D.(1);Rodríguez, C.(2);Mesonero, F.(3);Vicuña, M.(2);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);Hernández Martínez, Á.(6); Arroyo, M.(7);Vera, I.(8); Ruiz-Cerulla, A.(9);Sicilia, B.(10);Cabello Tapia, M.J.(11);Muñoz Villafranca, C.(12);Castro-Poceiro, J.(13);Martínez Cadilla, J.(14);Sierra-Ausín, M.(15);Vázquez Morón, J.M.(16);Montil Miguel, E.(17);Bermejo, F.(18);Royo, V.(19);Calafat, M.(20);González-Muñoza, C.(21);Leo Carnerero, E.(22);Manceñido Marcos, N.(23);Torrealba, L.(24); Alonso-Galán, H.(25);Benítez, J.M.(26);Ber Nieto, Y.(27);Diz-Lois Palomares, M.T.(28);García, M.J.(29);Muñoz, J.F.(30);Armesto González, E.M.(31);Calvet, X.(32); Hernández-Camba, A.(33);Madrigal Domínguez, R.E.(34);Menchén, L.(35);Pérez Calle, J.L.(36);Piqueras, M.(37);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 11:12 AM
P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Naftali*1,2, A. Ein Dor Abarbanel3, N. Ruhimovich2, A. Bar-Gil Shitrit4, F. Sklerovsky-Benjaminov1,2, H. Shirin1,3, S. Matalon1,3, T. Ziv Baran5, E. Broide1,3

Created: Friday, 22 February 2019, 9:41 AM
P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Farkas1, K.J. Szántó1, D. Kata2, I. Földesi2, T. Ferenci3, M. Rutka1, D. Pigniczki1, R. Bor1, A. Fábián1, Z. Szepes1, F. Nagy1, T. Molnár1

Created: Thursday, 30 January 2020, 10:12 AM
P676: Burden of depression and anxiety among inflammatory bowel disease patients in a national cohort in Israel – Data from the EPI-IIRN
Year: 2022
Source: ECCO'22
Authors: Mekori - Domachevsky, E..(1);Ziv - Baran, T.(2);Loewenberg Weisband, Y.(3);Greenfeld, S.(4);Kariv, R.(4);Erez, M.(5);Friss, F.(6);Focht, G.(6);Turner, D.(6);Ben - Horin, S.(1);Kopylov, U.(1);
Created: Friday, 11 February 2022, 3:56 PM
P676: Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.*1, Sakuraba A.2, Wang A.3, Macaulay D.4, Schemerold L.4, Yang M.5, Skup M.3

Created: Wednesday, 20 February 2019, 10:36 AM
P676: Correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: Data from the tofacitinib OCTAVE clinical trials
Year: 2018
Source: ECCO '18 Vienna
Authors:

B.G. Feagan1, C.Y. Ha2, P.R. Taub3, D. Quirk4, C.I. Nduaka4, L. Salese4, G. Chan4, G.S. Friedman4, W. Wang4, C. Su4, W. Reinisch5*

Created: Thursday, 21 February 2019, 9:14 AM
P676: Intestinal ultrasound accurately predicts therapy failure in Crohn's disease patients during a biologics-induced remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Albshesh, A.(1)*;Abend, A.(2); Margalit Yehuda, R.(1);Mahajna, H.(1);Ben-Horin, S.(1);Kopylov, U.(1);Carter, D.(1);
Created: Friday, 14 July 2023, 11:12 AM
P676: The impact to disease activity, iron and vitamin D deficiency on fatigue in IBD patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Atanassova*1, A. Georgieva1, D. Gerova2, M. Todorova2

Created: Friday, 22 February 2019, 9:41 AM
P676: The small intestinal microbiome in Crohn’s disease is characterised by increased luminal diversity and stable mucosa-associated communities
Year: 2021
Source: ECCO'21 Virtual
Authors: Wauters, L.(1,2);Tito, R.(3,4);Ceulemans, M.(2);Moens, A.(1,2);Outtier, A.(1);Sabino, J.(1,2);Ferrante, M.(1,2);Vermeire, S.(1,2);Vanuytsel, T.(1,2);Raes, J.(4,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P677 It’s time to grow up: what is it like to transition from the paediatric to adult inflammatory bowel disease service?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Keightley1,2, R. Prematunga1, P. Hoffmann3, K. Subramaniam2,4

Created: Thursday, 30 January 2020, 10:12 AM
P677: Azathioprine dosing and metabolite measurement in paediatric inflammatory bowel disease—does one size fit all?
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Tresman*, M. Mutalib, J. Kammermeier, R. Vora

Created: Thursday, 21 February 2019, 9:14 AM
P677: Combination of vedolizumab and exclusive enteral nutrition in patients with moderate to severe Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kang, J.(1,2,3);Wang, J.(1,2,3);Lu, Y.(4);Li, J.(1,2,3);Su, J.(1,2,3);Ying, A.(1,2,3);Ren, H.(1,2,3);Zhou, Q.(1,2,3);Wang, Y.(1,2,3);Ding, Y.(1,2,3);An, P.(1,2,3)*;
Created: Friday, 14 July 2023, 11:12 AM
P677: Effect of late faecal loss of infliximab on treatment response of inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. AlborziAvanaki*1, H. Rezvan1, N. Ebrahimi Daryani1, N. Ale Taha1

Created: Friday, 22 February 2019, 9:41 AM
P677: Fungal abundance is related to inflammatory status in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Herrera De Guise, C.M.(1); Sarrabayrouse, G.(2);Varela, E.(2);Robles, V.(1);Borruel, N.(1);Mayorga, L.F.(1);Casellas, F.(1);Ibarz, A.(2);Perez, Z.(1);Robles, M.(1);Guarner, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P677: Impact of patient reported outcomes, coping strategies and psychosocial factors on medication adherence in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chao C.-Y.*1,2, Lemieux C.1, Afif W.1, Bitton A.1, Wild G.1, Bessissow T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P677: Patients with Inflammatory Bowel Diseases on anti-TNF treatment have impaired antibody production after Anti-SARS-CoV-2 vaccination: Results from a Panhellenic registry
Year: 2022
Source: ECCO'22
Authors: Zacharopoulou, E.(1);Orfanoudaki, E.(2);Kitsou, V.(3);Tzouvala, M.(1);Tribonias, G.(1);Mantzaris, G.J.(4);Viazis, N.(4);Christidou, A.(4);Almpani, F.(4);Karmiris, K.(5);Theodoropoulou, A.(5);Tsafaridou, M.(2);Michopoulos, S.(6);Zampeli, E.(6);Papathanasiou, E.(6);Michalopoulos, G.(7);Tigkas, S.(7);Karatzas, P.(8);Laoudi, E.(8);Liatsos, C.(9);Kyriakos, N.(9);Mylonas, I.(9);Theocharis, G.(10);Koutroubakis, I.E.(2);Bamias, G.(3);
Created: Friday, 11 February 2022, 3:56 PM